美国 · 平台与数据 · Morningstar
Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026
Data included dose levels of 6, 7 and 8 MBq. PSA50, PSA80 and PSA90 represent maximum PSA declines of at least 50%, 80% and 90% from baseline, respectively. No dose-limiting…
在 Morningstar 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)
